Goal of Workshop: This NINDS/NIA sponsored workshop brings together leading experts and researchers from around the world to discuss the latest advancements and challenges in the field of anti-beta amyloid passive immunotherapy.

All times are Eastern Standard (EST).

Click here to download the printable agenda.

DAY 1 - September 28, 2023

8:30 amWelcomeFrancesca Bosetti
NINDS
8:35 amIntroductionWalter Koroshetz
NINDS
Session 1

Clinical Overview
Moderators:
Steve Greenberg
Massachusetts General Hospital
Stephen Salloway
Brown University
Rod Corriveau
NINDS

 
8:45 amOverview of anti-amyloid immunotherapy for Alzheimer’s dementiaDavid Clifford
Washington University
9:05 amWhat is known about Amyloid-related imaging abnormalities (ARIA)- E and ARIA- H?Reisa Sperling
Massachusetts General
Hospital
9:25 amLessons learned from CAA-related inflammationSteven Greenberg
Massachusetts General
Hospital
9:45 amNeuropathological studies in patients treated with anti-beta amyloid antibodies with ARIAJames Nicoll
University of Southampton, UK – VIRTUAL
10:05 amAdvanced methods for BBB imagingJohn Detre
University of Pennsylvania
10:25 amLessons learned from clinical trials: Identification and clinical management of patients at risk for adverse events related to ARIAKaren Smirnakis
Biogen
10:45 amBreak  
11:00 amPanel Discussion
Moderator: Clinton Wright (NINDS)

Panelists:
Anand Viswanathan
MGH
Susan Catalano
Capsida Biotherapeutics
Michael Irizarry
Eisai
Shari Ling
CMS

Session 2Basic Mechanisms Overview
Moderators:
Mark Fisher
University of California, Irvine
Donna Wilcock
Indiana University
Rod Corriveau
NINDS		 
11:40 pmCerebral Amyloid Angiopathy, Microvascular Disease, and MicrohemorrhageMark Fisher
University of California, Irvine
12:00 pmCAA and neurovascular dysfunction: role of innate immunity and ApoE4–Costantino Iadecola
Cornell University
12:20 pmLunch Break (on your own) 
1:15 pmBlood-Brain Barrier breakdown and other vascular compromise that can occur when anti-beta-amyloid passive immunotherapy is used: Basic Disease-related science of ARIA and Basic mechanisms of BBB breakdown in ARIA.Donna Wilcock
Indiana University
1:35 pmPanel Discussion
NIH Moderator:
Lanier Heyburn
NINDS		Panelists:
Gary Rosenberg
University of New Mexico
Helene Benveniste
Yale University
Thierry Bussiere
Biogen
2:15 – 2:30 pmBreak 
Session 3Future Research Ideas and Preclinical Research Ideas
Moderators:
Katerina Akassoglou
Gladstone Institute, UCSF
Costantino Iadecola
Cornell
Linda McGavern
NINDS
2:30 pmWhat Animal models would be useful in understanding CAA and ARIA.William Van Nostrand
Univ. Rhode Island – VIRTUAL
2:50 pmNonhuman primate models of CAA and ARIALary Walker
Emory University
3:10 pmStrategies to protect the BBB in persons taking anti-amyloid Ab therapyKaterina Akassoglou
Gladstone Institute, UCSF
3:30 pmMedin as an Alternative Target for prevention of vascular damageJonas J. Neher
German Center for Neurodegenerative Disease, Tubingen
3:50 pmProtecting endothelial barrier and pericytes with activated protein C mutant: effect of APOE4Bersilav Zlokovic
USC – VIRTUAL
4:10 pmPanel Discussion
NIH Moderator:
Francesca Bosetti
NINDS		Panelists:
John Sims
Ely Lilly
Marion Buckwalter
Stanford University
Lawrence Honig
Columbia University
4:50 pmDay 1 Closing Remarks 
5:00 pmAdjourn 

DAY 2 - September 29, 2023

Session 3 Future Research Ideas (continued) Clinical Research Ideas Moderators:  Alessandra Rovescalli NIA John Detre   University of Pennsylvania Cynthia Lemere Brigham and Women’s Hospital
8:30 am Risks associated with cerebrovascular disease comorbidities and their treatments.  Can anti-beta-amyloid passive immunotherapy be safely combined with anti-thrombotic agents? Stephen Salloway   Brown University
8:50 am How to determine risk of concomitant anti-thrombotic or thrombolytic therapy in persons with CAA.  Sherry Chou Northwestern University
9:10 am Patient stratification: can we identify patients who are not susceptible (or least susceptible) to adverse ARIA events as a result of anti-beta-amyloid passive immunotherapy. David Knopman   Mayo Clinic
9:30 am ARIA-E, iatrogenic CAA-ri and the ARIA Paradox. Lessons learned from the last 10 years of biomarkers research and experience on CSF anti-amyloid (auto)antibody testing for ARIA prediction and monitoring. Fabrizio Piazza University of Milan-Bicocca
9:50 am Emerging targets for immunotherapy. Cynthia Lemere   Brigham and Women’s Hospital
10:10 am Panel Discussion Moderator: Alessandra Rovescalli NIA Panelists: Scott Turner Georgetown University Teresa Buracchio FDA Maria Carrillo Alzheimer’s Association Hanzhang Lu Johns Hopkins University
10:50am Break
11:00am Scientific Gaps and Priorities
12:00pm Conclusion and Final Remarks Richard Hodes  NIA
12:15 pm Meeting Adjourns
Session 3 Future Research Ideas(continued)

Clinical Research Ideas
Moderators:
Alessandra RovescallI
NIA
John Detre
University of Pennsylvania
Cynthia Lemere
Brigham and Women’s Hospital

 
8:30 amRisks associated with cerebrovascular disease comorbidities and their treatments. Can anti-beta-amyloid passive immunotherapy be safely combined with anti-thrombotic agents?Stephen Salloway
Brown University
8:50 amHow to determine risk of concomitant anti-thrombotic or thrombolytic therapy in persons with CAA.Sherry Chou
Northwestern University
9:10 amPatient stratification: can we identify patients who are not susceptible (or least susceptible) to adverse ARIA events as a result of anti-beta-amyloid passive immunotherapy.David Knopman
Mayo Clinic
9:30 amARIA-E, iatrogenic CAA-ri and the ARIA Paradox. Lessons learned from the last 10 years of biomarkers research and experience on CSF anti-amyloid (auto)antibody testing for ARIA prediction and monitoring.Fabrizio Piazza
University of Milan-Bicocca
9:50 amEmerging targets for immunotherapy.Cynthia Lemere
Brigham and Women’s
Hospital
10:10 amPanel Discussion
Moderator:
Alessandra Rovescalli
NIA		Panelists:
Scott Turner
Georgetown University
Teresa Buracchio
FDA
Maria Carrillo
Alzheimer’s Association
Hanzhang Lu
Johns Hopkins University
10:50am Break 
11:00amScientific Gaps and Priorities 
12:00pmConclusion and Final RemarksRichard Hodes
NIA
12:15 pmMeeting Adjourns 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.